The potential benefits of effective BCR::ABL1 TKI treatment, even with accompanying AEs, may outweigh the potential risks of progression-related mortality in patients with CP-CML and Ph+ ALL receiving second- or third-line therapy. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.